Skip to main content
SEARCH TEMPLE HEALTH
Neurosciences Center

AtRial Cardiopathy and Antithrombotic Drugs In Prevention After Cryptogenic Stroke

view all Clinical Trials

Overview

Objectives

  • Primary: To test the hypothesis that apixaban is superior to aspirin for the prevention of recurrent stroke in patients with cryptogenic ischemic stroke and atrial cardiopathy.
  • Secondary: To test the hypothesis that the relative efficacy of apixaban over aspirin increases with the severity of atrial cardiopathy.

Contact

For more information about this trial or to inquire about eligibility, call 215-707-7845 or email sandra.combs@tuhs.temple.edu.